These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 22509668)

  • 21. New options for the management of castration-resistant prostate cancer: a case perspective.
    Goetz D
    J Natl Compr Canc Netw; 2011 Feb; 9 Suppl 3():S13-23; quiz S24. PubMed ID: 21357663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metastatic hormone refractory prostate cancer: recent advances in standard treatment paradigm, and future directions.
    Keizman D; Maimon N; Gottfried M
    Am J Clin Oncol; 2014 Jun; 37(3):289-96. PubMed ID: 22772426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A renaissance in the medical treatment of advanced prostate cancer.
    Rove KO; Flaig TW
    Oncology (Williston Park); 2010 Dec; 24(14):1308-13, 1318. PubMed ID: 21294475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED.
    Aragon-Ching JB
    Asian J Androl; 2016; 18(3):444-5. PubMed ID: 26510505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer.
    Singapore Cancer Network (SCAN) Genitourinary Cancer Workgroup
    Ann Acad Med Singap; 2015 Oct; 44(10):397-405. PubMed ID: 26763057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New therapeutic agents for castration-refractory prostate cancer.
    Patten DY; Sartor O
    Clin Genitourin Cancer; 2009 Aug; 7(2):E4-6. PubMed ID: 19692323
    [No Abstract]   [Full Text] [Related]  

  • 27. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis.
    Suzman DL; Antonarakis ES
    Oncology (Williston Park); 2014 Oct; 28(10):880, 882. PubMed ID: 25323614
    [No Abstract]   [Full Text] [Related]  

  • 28. Expanding treatment options for metastatic prostate cancer.
    Antonarakis ES; Eisenberger MA
    N Engl J Med; 2011 May; 364(21):2055-8. PubMed ID: 21612475
    [No Abstract]   [Full Text] [Related]  

  • 29. [New hope in the treatment of advanced cancer of the prostate in 2012].
    Massard C
    Bull Cancer; 2012 Jul; 99 Suppl 1():S3. PubMed ID: 23767051
    [No Abstract]   [Full Text] [Related]  

  • 30. Agents that target androgen synthesis in castration-resistant prostate cancer.
    Ferraldeschi R; de Bono J
    Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Castration-refractory prostate cancer: new therapies, new questions.
    Appleman LJ
    Oncology (Williston Park); 2010 Dec; 24(14):1318-9, 1326. PubMed ID: 21294476
    [No Abstract]   [Full Text] [Related]  

  • 32. [Inhibitors of the key enzymes of androgen synthesis: potential agents as targets for prostate cancer].
    Takeda M; Hosaka M
    Nihon Rinsho; 2000 Jul; 58 Suppl():312-6. PubMed ID: 11022738
    [No Abstract]   [Full Text] [Related]  

  • 33. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
    Nabhan C
    N Engl J Med; 2010 Nov; 363(20):1966-7; author reply 1968. PubMed ID: 21067391
    [No Abstract]   [Full Text] [Related]  

  • 34. Abiraterone and increased survival in metastatic prostate cancer.
    Berruti A; Pia A; Terzolo M
    N Engl J Med; 2011 Aug; 365(8):766; author reply 767-8. PubMed ID: 21864182
    [No Abstract]   [Full Text] [Related]  

  • 35. Castration-refractory prostate cancer: New drugs in the pipeline.
    Schrijvers D; Van Erps P; Cortvriend J
    Adv Ther; 2010 May; 27(5):285-96. PubMed ID: 20532721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New treatment options for patients with metastatic castration-resistant prostate cancer.
    Higano CS
    Cancer Treat Rev; 2012 Aug; 38(5):340-5. PubMed ID: 21944872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.
    Attard G; Belldegrun AS; de Bono JS
    BJU Int; 2005 Dec; 96(9):1241-6. PubMed ID: 16287438
    [No Abstract]   [Full Text] [Related]  

  • 38. Concerns about Provenge simmer as CMS ponders coverage.
    Goozner M
    J Natl Cancer Inst; 2011 Feb; 103(4):288-9. PubMed ID: 21303996
    [No Abstract]   [Full Text] [Related]  

  • 39. Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer.
    Pal SK; Sartor O
    Asian J Androl; 2011 Sep; 13(5):683-9. PubMed ID: 21602834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is this a true renaissance for the treatment of prostate cancer?
    Pili R
    Oncology (Williston Park); 2010 Dec; 24(14):1327-8. PubMed ID: 21294477
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.